期刊文献+

氘代AZD9291的合成 被引量:4

Synthesis of Deuterated AZD9291
下载PDF
导出
摘要 吲哚和2,4-二氯嘧啶经偶联反应制得3-(2-氯嘧啶-4-基)-1H-吲哚(1);1与CD3I经取代反应制得3-(2-氯嘧啶-4-基)-1-(甲基-d3)-吲哚(2);2经两步亲核取代反应制得N'-(2-二甲基氨基乙基)-2-甲氧基-N'-甲基-N-{4-[1-(甲基-d3)吲哚-3-基]嘧啶-2-基}-5-硝基苯-1,4-二胺(4);4经还原后,与氯丙酰氯发生缩合反应合成了氘代AZD9291,总收率8.5%,其结构经1H NMR,13C NMR和ESI-MS表征。 The synthesis of deuterated AZD9291 was reported. 3-( 2-Chloropyrimidin-4-yl)-1H- indole( 1) was prepared by coupling reaction of indole with 2,4-dichloropyrimidine. 3-( 2-Chloropyrimidin-4-yl)-1-( methyl-d3)-lindole( 2) was obtained by substitution reaction of 1 with iodomethane-d3. N'-( 2-dimethylaminoethyl)-2-methoxy-N'-methyl-N-{ [4-( 1- methyl-d3) indol-3-yl]pyrimidin-2-yl} benzene-1,2,4-triamine( 4) was obtained by two substitution reactions from 2. Then deuterated AZD9291 in total yield of 8. 5% was synthesized by condensation reaction following the reduction 4. The structure was confirmed by1 H NMR,13 C NMR and ESI-MS.
出处 《合成化学》 CAS CSCD 2016年第3期263-265,276,共4页 Chinese Journal of Synthetic Chemistry
关键词 AZD9291 表皮生长因子受体 氘代药物 药物合成 AZD9291 EGFR deuterated drug drug synthesis
  • 相关文献

参考文献8

  • 1Ling C I-I, Chen G, Chen G D. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo[ J]. Int J Cancer,2012,131:2411 - 2419.
  • 2Robert F, Gautier D, Dubrulle B. The solar system D/ H ratio: Observations and theories [ J ]. Space Sci Rev, 2000,92:201 - 224.
  • 3Sharma R, Strelevitz T J, Gao H Y, et al. Deuterium isotope effects on drug pharmacokiuetics. I. System de- pendent effects of specific deuteration with aldehyde oxidase cleared drugs[ J]. Drug Metabolism and Dispo- sition ,2012,40:625 - 634.
  • 4Thomas G G. Using deuterium in drug discovery:Leav- ing the label in the drug [ J ]. J Med Chem, 2014,57 (9) :3595 - 3611.
  • 5Alla K. Heavy drugs draw heavy interest from pharma backers[J]. Nature Medicine,2013,19(6) :656 -656.
  • 6Darren A E C, Susan A, Serban G, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[ J]. Canc- er Discov ,2014,4(9) : 1046 - 61.
  • 7Steuer C E, Khuri F R, Ramalingam S S. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer [ J ]. Cancer,2015,121(8) :E1 -6.
  • 8Finlay M R V, Anderton M, Ashton S. Discovery of a potent and selective EGFR inhibitor ( AZD9291 ) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor [ J ]. J Med Chem,2014,57 ..8249 - 8267.

同被引文献13

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部